Evidence map›Paper›PMID 36819883›Full record

ArticleEuropean heart journal. Case reports2023

Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series.

Samet Yılmaz, Yakup Çetinkaya, Hasan Akkaya, Arif Arısoy

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Samet YılmazCardiology Department, Nigde Omer Halisdemir University Research and Training Hospital, Aşağı Kayabaşı Mahallesi Hastaneler Cad 51100, Niğde Merkez, Nigde, Turkey.ORCID https://orcid.org/0000-0003-4738-3478
Yakup ÇetinkayaCardiology Department, Nigde Omer Halisdemir University Research and Training Hospital, Aşağı Kayabaşı Mahallesi Hastaneler Cad 51100, Niğde Merkez, Nigde, Turkey.ORCID https://orcid.org/0000-0002-0689-7221
Hasan AkkayaCardiology Department, Nigde Omer Halisdemir University Medicine Faculty Education and Research Hospital, Aşağı Kayabaşı Mahallesi Hastaneler Cad 51100, Niğde Merkez, Nigde, Turkey.ORCID https://orcid.org/0000-0003-0853-2549
Arif ArısoyDepartment of Cardiology, Medical Park Hospital, Yeşilırmak, Vali Zekai Gümüşdiş Blv. No: 29, 60230 Tokat Merkez, Tokat, Turkey.ORCID https://orcid.org/0000-0002-0077-1310
Niğde Ömer Halisdemir Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Essential thrombocythaemia (ET) is defined as a myeloproliferative neoplasm with a tendency to haemorrhage and thrombosis. Acute coronary thrombosis can be observed in 1 out of 10 patients. The management of ET patients with acute coronary syndrome (ACS) is a complex clinical condition that requires close follow-up. Case summary: Discussion: Platelet counts returned to the normal range with ticagrelor treatment given after ACS in patients with JAK+ ET. Monitoring platelet reduction in JAK+ patients with P2Y12 inhibition is thought to be important for new treatment options.

Indexed as

Acute coronary syndromeCase seriesEssential thrombocythaemiaJAK-STAT pathwayP2Y12 receptorTicagrelor

Identifiers

PMID36819883
PMCPMC9933940
OpenAlexW4320727216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.